קם-רהו די I.M

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

ANTI-D IMMUNOGLOBULINS

Disponível em:

KAMADA LTD, ISRAEL

Código ATC:

J06BB01

Forma farmacêutica:

תמיסה להזרקה

Composição:

ANTI-D IMMUNOGLOBULINS 150 MCG/ML

Via de administração:

תוך-שרירי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

KAMADA LTD, ISRAEL

Grupo terapêutico:

ANTI-D (RH) IMMUNOGLOBULIN

Área terapêutica:

ANTI-D (RH) IMMUNOGLOBULIN

Indicações terapêuticas:

Pregnancy/other obstetric conditions, Suppression of Rh immunization in non-sensitized Rh0 (D) negative women delivering an Rh0 positive baby or when the baby's Rh type is unknown. Suppression of Rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. Kam Rh0 -D IM should be given within 72 hours of the event. It may be given even after up to one month although efficacy may be somewhat reduced.Transfusion: Suppression of Rh isoimmunization in Rh0 (D) antigen-negative patients transfused with Rh0 (D) antigen-positive RBCs of blood components containing Rh0 (D) antigen-positive RBCs . Initate treatment within 72 hours of exposure.

Data de autorização:

2022-01-31